Design Space Verification for Tablet Dosage Form Using Modeling

Thursday, October 20, 2011: 1:10 PM
Symphony III (Hilton Minneapolis)
Mary T. am Ende1, Thomas P. Garcia2, Kim Vukovinsky3, Penelope Butterell4, Alex Chueh5, Bernd Schuemmelfeder6, Vincent E. McCurdy2 and Daniel Gierer1, (1)Pharmaceutical Development, Pfizer Worldwide Research and Development, Groton, CT, (2)Global CMC, Pfizer Worldwide Research and Development, Groton, CT, (3)PharmaTherapeutics, Pfizer Worldwide Research and Development, Groton, CT, (4)Gqts, Pfizer Global Supply, Zaventem, Belgium, (5)Global Manufacturing Services, Pfizer Global Supply, Pearl River, NY, (6)Global Manufacturing Services, Pfizer Global Supply, Freiburg, Germany

Quality by Design principles are well established in the pharmaceutical industry.  It is becoming common place to develop the design space for a drug product and include it in the regulatory filing.  There are a broad range of methods to establish design space, some of which are focused on individual unit operations and others that take a holistic view of the entire product processing.  A new challenge is developing approaches for verifying the design space for commercial production, especially for those defined using data obtained from modeling or small scale experiments.  In this talk, a proposal for verifying the design space for a drug product with multiple CPPs, KPPs and CQAs will be discussed using principles of scale-dependencies, use of precedented models, and (when necessary) large scale confirmation batches.

Extended Abstract: File Not Uploaded